Velora Therapeutics, Inc.ready
velora-vlr2876-rfp.pdf
Velora seeks a CDMO partner to execute process development, analytical qualification, and a 25 kg cGMP campaign of VLR-2876 tosylate salt (covalent KRAS-G12D inhibitor) by September 2026 in support of Phase 3 pivotal stu…